FDA’s Arista To India: What’s Your Everest?
This article was originally published in PharmAsia News
Executive Summary
For the quality-hit Indian drug industry, a senior investigator from the U.S. FDA has driven home a few candid messages – lead by example and clean up. Speaking at a conference in Mumbai, the representative pinned the responsibility on proactive corporate leadership to get the industry to follow best practices.
You may also be interested in...
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.
Could Indian heart stent study findings lead to price cuts?
India’s top regulatory agencies are weighing up the findings from a study it had commissioned that looks at the clinical benefits of heart stents, with the possible aim of using the results to back the use of cheaper, locally-produced devices.